ACTRN12613001154796
尚未招募
2 期
A phase 2 trial of cyclophosphamide as prophylaxis for graft-versus-host disease after HLA-identical allogeneic donor transplantation using reduced intensity conditioning therapy
Westmead Hospital0 个研究点目标入组 24 人2013年10月16日
概览
- 阶段
- 2 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Graft versus Host Disease
- 发起方
- Westmead Hospital
- 入组人数
- 24
- 状态
- 尚未招募
- 最后更新
- 6年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Age 15\-70 years
- •2\.High risk hematological malignancy suitable for treatment with an allogeneic transplant (acute leukaemia in first remission with poor risk cytogenetics or unfavourable gene mutation profile, or in second or subsequent remission, chronic myeloid leukaemia in first chronic phase not responding to tyrosine kinase inhibitor therapy, poor risk myelodysplastic syndrome, Hodgkin or non\-Hodgkin lymphoma failing conventional therapy).
- •3\.Suitable HLA\-matched related donor (6/6 match for A, B, DRB1\) or unrelated volunteer donor (8 locus match for A, B, C, and DRB1 at allelic level) identified and available.
排除标准
- •1\. Serious organ dysfunction or uncontrolled infection
- •2\.HIV positive
- •3\.Uncontrolled hepatitis B or C.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
Cyclophosphamide and Dexamethasone in combination with Ixazomib (ICD), in relpased or refractory multiple myeloma patients.Relasped and Refractory Mulitple MyelomaMedDRA version: 18.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-004511-36-GBniversity Of Leeds250
进行中（未招募）
1 期
Graft-versus-host response after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantatioWomen and men with a hematologic malignancy for which a reduced-intensity conditioning allo-SCT is indicatedMedDRA version: 19.0Level: PTClassification code 10053239Term: Prophylaxis against graft versus host diseaseSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2016-002129-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)88
进行中（未招募）
不适用
An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - NDEUCTR2007-006037-13-ITOSPEDALE POLICLINICO S. MATTEO
进行中（未招募）
2 期
Short treatment with the drug cyclophosphamide in bowel cancerStage II-IVA diagnosed colorectal cancerCancerBowel cancerISRCTN12508004Cardiff University500
已完成
2 期
A parallel randomised phase II trial of cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP) chemotherapy with or without Bortezomib in relapsed mantle cell lymphomaRelapsed or refractory mantle cell lymphomaCancerMantle cell lymphomaISRCTN20159589Plymouth Hospitals NHS Trust (UK)90